Tocopherol-based pharmaceutical systems
    21.
    发明授权
    Tocopherol-based pharmaceutical systems 失效
    基于生育酚的制药系统

    公开(公告)号:US5364631A

    公开(公告)日:1994-11-15

    申请号:US18913

    申请日:1993-02-17

    IPC分类号: A61K9/127 A61K31/415

    摘要: A method for making a pharmaceutical composition is described. The composition is comprised of an organic acid derivative of alpha tocopherol, and may additionally comprise other lipids. The composition may be in the form of liposomes, and as such are associated with or entrap a bioactive agent. Particularly suited for such systems are drugs stable at acidic pH, for example drugs having imidazole groups, such as pilocarpine. The composition requires a stabilizer to maintain the bilayer phase of the organic acid derivative of alpha tocopherol in a low pH environment. Such a stabilizer is for example a detergent. Upon in vivo administration of the system and concomitant increase of pH, viscosity of the preparation increases.

    摘要翻译: 描述制备药物组合物的方法。 组合物由α-生育酚的有机酸衍生物组成,并且还可以包含其它脂质。 组合物可以是脂质体的形式,因此与生物活性剂相关联或截留生物活性剂。 特别适用于这种系统是在酸性pH下稳定的药物,例如具有咪唑基团的药物,如毛果芸香碱。 该组合物需要稳定剂以在低pH环境中维持α-生育酚的有机酸衍生物的双相。 这种稳定剂是例如洗涤剂。 在系统的体内给药和伴随pH的增加时,制剂的粘度增加。

    Stable plurilamellar vesicles
    22.
    发明授权
    Stable plurilamellar vesicles 失效
    稳定的多层囊泡

    公开(公告)号:US5169637A

    公开(公告)日:1992-12-08

    申请号:US679569

    申请日:1991-04-02

    IPC分类号: A61K9/127

    CPC分类号: A61K9/127 A61K9/1277

    摘要: A new and substantially improved type of lipid vesicle, called stable plurilamellar vesicles (SPLVs), are described, as well as the process for making the same and X-ray diffraction methods for identifying the same. SPLVs are characterized by lipid bilayers enclosing aqueous compartments containing one or more entrapped solutes, the concentration of such solutes in each aqueous compartment being substantially equal to the emunization of solutes used to prepare the SPLVs. The bilayers of SPLVs are substantially non-compressed. SPLVs are stable during storage and can be used in vivo for the sustained release of compounds and in the treatment of disease.

    摘要翻译: 描述了称为稳定多层囊泡(SPLV)的新的和基本上改进的类型的脂质囊泡,以及制备相同的方法和用于鉴定其的X射线衍射方法。 SPLV的特征在于包裹含有一个或多个截留的溶质的水性隔室的脂质双层,每个水分隔室中的这种溶质的浓度基本上等于用于制备SPLV的溶质的排出。 SPLV的双层基本上是非压缩的。 SPLV在储存期间是稳定的,并且可以在体内用于化合物的持续释放和疾病的治疗。

    Lipid-dependent diagnostic assays
    26.
    发明授权
    Lipid-dependent diagnostic assays 失效
    脂质依赖性诊断测定

    公开(公告)号:US06261792B1

    公开(公告)日:2001-07-17

    申请号:US08441567

    申请日:1995-05-15

    IPC分类号: C12Q156

    摘要: For use in a lipid-dependent diagnostic assay, a stable aqueous suspension of a phospholipid which normally has a hexagonal (HII) organization when dispersed in an aqueous medium without detergent, the suspension containing the phospholipid, a detergent, and an aqueous phase. In the stable suspension, the phospholipid remains in suspension at a temperature of 25° C. for at least one hour. The suspension is suitable for providing the phospholipid to an assay for lupus anticoagulants which includes the step of pre-incubating a test sample with the phospholipid.

    摘要翻译: 为了用于脂质依赖性诊断测定法,当分散在不含洗涤剂的水性介质中时,通常具有六边形(HII)组织的磷脂的稳定水性悬浮液,含有磷脂的悬浮液,洗涤剂和水相。 在稳定的悬浮液中,磷脂在25℃的温度下保持悬浮至少1小时。 该悬浮液适用于将磷脂提供给用于狼疮抗凝剂的测定法,其包括用磷脂预孵育测试样品的步骤。

    Liposomal hydrolysis-promoting hydrophobic taxane derivatives
    28.
    发明授权
    Liposomal hydrolysis-promoting hydrophobic taxane derivatives 失效
    脂质体水解促进疏水紫杉烷衍生物

    公开(公告)号:US6051600A

    公开(公告)日:2000-04-18

    申请号:US805184

    申请日:1997-02-27

    摘要: Provided herein is a taxane having a hydrocarbon attached at the 2' and/or 7 positions, the hydrocarbon's alpha position being occupied by a "hydrolysis-promoting group" ("HPG"). Substitution of an HPG for the methylene unit ordinarily occupying the alpha position allows for enhanced in vivo hydrolysis of the hydrocarbon-taxane bond, and hence, for enhanced taxane therapeutic activity. Also provided herein are taxane-containing compositions, and methods of administering taxanes to animals, including those afflicted with cancers.

    摘要翻译: 本文提供了具有在2'和/或7位上连接的烃的紫杉烷,烃的α位置被“水解促进基团”(“HPG”)占据。 通常占据α位置的亚甲基单元的HPG的取代允许增强体系中的烃 - 紫杉烷键的体内水解,从而增强紫杉烷的治疗活性。 本文还提供含紫杉烷的组合物,以及将紫杉烷类药物给予动物(包括患有癌症的那些)的方法。

    Interdigitation-fusion liposomes containing arachidonic acid metabolites
    30.
    发明授权
    Interdigitation-fusion liposomes containing arachidonic acid metabolites 失效
    含有花生四烯酸代谢物的交叉指导融合脂质体

    公开(公告)号:US5882678A

    公开(公告)日:1999-03-16

    申请号:US339964

    申请日:1994-11-15

    IPC分类号: A61K9/127 A61K31/557 A61L2/00

    摘要: This invention provides an interdigitation-fusion liposome comprising an arachidonic acid metabolite, a lipid bilayer comprising a lipid and an aqueous compartment comprising a release-inhibiting buffer. Preferred arachidonic acid metabolites are the prostaglandins, particularly PGE.sub.1. The liposomal formulations can be used to treat animals, particularly humans, for diseases, disorders or conditions which can be ameliorated by prostaglandins, e.g., cell activation/adhesion disorders and inflammatory disorders.

    摘要翻译: 本发明提供了一种包含花生四烯酸代谢物的交叉指导 - 融合脂质体,包含脂质的脂质双层和包含释放抑制缓冲液的水性隔室。 优选的花生四烯酸代谢物是前列腺素,特别是PGE1。 脂质体制剂可用于治疗可由前列腺素改善的疾病,病症或病症的动物,特别是人,例如细胞活化/粘附障碍和炎症性疾病。